89bio, Inc. (ETNB)
NASDAQ: ETNB · Real-Time Price · USD
8.76
+0.38 (4.53%)
Nov 22, 2024, 4:00 PM EST - Market closed
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
The company was incorporated in 2018 and is headquartered in San Francisco, California.
89bio, Inc.
Country | United States |
Founded | 2018 |
IPO Date | Nov 11, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 70 |
CEO | Rohan Palekar |
Contact Details
Address: 142 Sansome Street, Second Floor San Francisco, California 94104 United States | |
Phone | 415 432 9270 |
Website | 89bio.com |
Stock Details
Ticker Symbol | ETNB |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001785173 |
CUSIP Number | 282559103 |
ISIN Number | US2825591033 |
Employer ID | 83-1114349 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Rohan Palekar | Chief Executive Officer and Director |
Quoc Le-Nguyen | Chief Technical Officer |
Dr. Harry Mansbach M.D. | Chief Medical Officer |
Ryan Stephen Martins | Chief Financial Officer |
Francis W. Sarena | Chief Operating Officer |
Shiva K. Natarajan CPA | Senior Vice President of Finance and Principal Accounting Officer |
Annie J. Chang M.B.A. | Vice President of Investor Relations and Corporate Communications |
Amanda Kurihara | Vice President of People and Culture |
Melissa Abel | Senior Vice President of Commercial Strategy |
Paul Shin | Senior Vice President of Research & Development Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | 8-K | Current Report |
Nov 13, 2024 | 424B5 | Filing |
Nov 12, 2024 | 424B5 | Filing |
Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 7, 2024 | 8-K | Current Report |
Nov 7, 2024 | 10-Q | Quarterly Report |